# A Relative Bioavailability Study of HRS9531 in Healthy Subjects

> **NCT05893576** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HRS9531
- **DRUG:** HRS9531

## Key facts

- **NCT ID:** NCT05893576
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2023-09-04
- **Final completion:** 2023-09-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893576, "A Relative Bioavailability Study of HRS9531 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05893576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*